← Leaderboards
Antoni Ribas
University Of California Los Angeles
$28,929,216
Attributed
$30,162,547
Total exposure
27
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,550,616 · 30
By mechanism
P01$32,135,527 · 9
R35$9,456,270 · 1
P50$3,545,364 · 2
R01$3,017,954 · 2
U54$2,180,668 · 1
T32$1,772,549 · 1
Top collaborators
- James R. Heath6 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Christopher Seet$1,554,283
- William Yang$988,650
- Guido Erwin Michael Eibl$7,914,971
- Heather Christofk$9,647,151
- Kathrin Plath$21,177,103
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaClinical TrialsProgramsResearch PersonnelResponseImmunotherapyResistanceBaseTumorSamplingMalignant NeoplasmsT-LymphocyteCellsFundingT-Cell ReceptorDesignImmuneMouse ModelCancer CellIn VivoEngineeringCancer ImmunotherapyGenerationsBraf Gene
Grant awards (93)
Next Generation Cancer Immunotherapies to Defeat Melanoma$936,000
R35 · FY2025 · CA · contact PI
Tumor Immunology and Immunotherapy (TII)$83,267
P30 · FY2025 · CA · contact PI
Combination Therapies to Defeat Melanoma Resistance$2,478,520
P01 · FY2024 · CA · contact PI
Next Generation Cancer Immunotherapies to Defeat Melanoma$889,199
R35 · FY2024 · CA · contact PI
Project 3: Modeling and overcoming resistance to melanoma immunotherapy$492,024
P01 · FY2024 · CA · contact PI
Administrative and Statistics Core$301,342
P01 · FY2024 · CA · contact PI
Tumor Immunology$145,300
P30 · FY2024 · CA · contact PI
Combination Therapies to Defeat Melanoma Resistance$2,556,789
P01 · FY2023 · CA · contact PI
Next Generation Cancer Immunotherapies to Defeat Melanoma$917,279
R35 · FY2023 · CA · contact PI
Project 3: Modeling and overcoming resistance to melanoma immunotherapy$507,562
P01 · FY2023 · CA · contact PI
Administrative and Statistics Core$310,859
P01 · FY2023 · CA · contact PI
Tumor Immunology$145,304
P30 · FY2023 · CA · contact PI
Combination Therapies to Defeat Melanoma Resistance$2,556,789
P01 · FY2022 · CA · contact PI
Next Generation Cancer Immunotherapies to Defeat Melanoma$936,000
R35 · FY2022 · CA · contact PI
Project 3: Modeling and overcoming resistance to melanoma immunotherapy$507,562
P01 · FY2022 · CA · contact PI
Administrative and Statistics Core$310,858
P01 · FY2022 · CA · contact PI
Tumor Immunology$145,304
P30 · FY2022 · CA · contact PI
Combination Therapies to Defeat Melanoma Resistance$2,608,967
P01 · FY2021 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$899,241
R35 · FY2021 · CA · contact PI
Project 3: Modeling and overcoming resistance to melanoma immunotherapy$517,920
P01 · FY2021 · CA · contact PI
Administrative and Statistics Core$317,203
P01 · FY2021 · CA · contact PI
Tumor Immunology$145,304
P30 · FY2021 · CA · contact PI
Combination Therapies to Defeat Melanoma Resistance$2,574,738
P01 · FY2020 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$899,241
R35 · FY2020 · CA · contact PI
Project 3: Modeling and overcoming resistance to melanoma immunotherapy$517,920
P01 · FY2020 · CA · contact PI
Administrative and Statistics Core$317,203
P01 · FY2020 · CA · contact PI
Repurposing of cancer therapeutics for treatment of patients with COVID-19 disease$183,000
U54 · FY2020 · CA
Tumor Immunology$71,440
P30 · FY2020 · CA · contact PI
Nanosystems Biology Cancer Center$1,997,668
U54 · FY2019 · CA
Immuno-Targeted Therapy for Melanoma$872,264
R35 · FY2019 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$899,241
R35 · FY2018 · CA · contact PI
Overcoming BRAF-inhibitor Resistance in Melanoma$1,688,850
P01 · FY2017 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$899,241
R35 · FY2017 · CA · contact PI
ADMINISTRATION$252,771
P01 · FY2017 · CA · contact PI
Overcoming BRAF-inhibitor Resistance in Melanoma$1,688,850
P01 · FY2016 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$899,241
R35 · FY2016 · CA · contact PI
ADMINISTRATION$252,771
P01 · FY2016 · CA · contact PI
Overcoming BRAF-inhibitor Resistance in Melanoma$1,688,850
P01 · FY2015 · CA · contact PI
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)$626,768
R01 · FY2015 · CA
Response and Acquired Resistance to PD-1 Blockade$551,291
R01 · FY2015 · CA · contact PI
Immuno-Targeted Therapy for Melanoma$409,323
R35 · FY2015 · CA · contact PI
ADMINISTRATION$252,771
P01 · FY2015 · CA · contact PI
Overcoming BRAF-inhibitor Resistance in Melanoma$1,638,184
P01 · FY2014 · CA · contact PI
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)$607,965
R01 · FY2014 · CA
Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen$496,790
P01 · FY2014 · CA · contact PI
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core$484,169
P01 · FY2014 · CA · contact PI
ADMINISTRATION$245,187
P01 · FY2014 · CA · contact PI
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...$217,272
P50 · FY2014 · CA · contact PI
Overcoming BRAF-inhibitor Resistance in Melanoma$1,726,864
P01 · FY2013 · CA · contact PI
Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen$629,729
P01 · FY2013 · CA · contact PI
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)$589,162
R01 · FY2013 · CA
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core$438,766
P01 · FY2013 · CA · contact PI
Academic Training in Medical Oncology$317,707
T32 · FY2013 · CA · contact PI
ADMINISTRATION$258,158
P01 · FY2013 · CA · contact PI
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...$204,135
P50 · FY2013 · CA · contact PI
Academic Training in Medical Oncology$65,267
T32 · FY2013 · CA · contact PI
Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen$674,507
P01 · FY2012 · CA · contact PI
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)$642,768
R01 · FY2012 · CA
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...$594,718
P50 · FY2012 · CA · contact PI
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core$467,624
P01 · FY2012 · CA · contact PI
Academic Training in Medical Oncology$322,328
T32 · FY2012 · CA · contact PI
Academic Training in Medical Oncology$68,072
T32 · FY2012 · CA · contact PI
Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen$677,575
P01 · FY2011 · CA · contact PI
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...$625,367
P50 · FY2011 · CA · contact PI
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core$468,055
P01 · FY2011 · CA · contact PI
Academic Training in Medical Oncology$316,308
T32 · FY2011 · CA · contact PI
Academic Training in Medical Oncology$66,919
T32 · FY2011 · CA · contact PI
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...$805,497
P50 · FY2010 · CA · contact PI
Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen$746,269
P01 · FY2010 · CA · contact PI
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core$482,531
P01 · FY2010 · CA · contact PI
Academic Training in Medical Oncology$304,451
T32 · FY2010 · CA · contact PI
ADOPTIVE TRANSFER OF MART-1 F5 TCR ENGINEERED PERIPHERAL BLOOD MONONUCLEAR CELLS$13,844
M01 · FY2010 · RR · contact PI
Academic Training in Medical Oncology$311,497
T32 · FY2009 · CA · contact PI
In Vivo Imaging of Antigen-Specific T Cells in Mice and Humans$257,250
P50 · FY2009 · CA · contact PI
A PHASE 2, OPEN-LABEL, SINGLE ARM CLINICAL$12,500
M01 · FY2009 · RR · contact PI
In Vivo Imaging of Antigen-Specific T Cells in Mice and Humans$258,046
P50 · FY2008 · CA · contact PI
A PHASE 2, OPEN-LABEL, SINGLE ARM CLINICAL TRIAL TO STUDY THE MECHANISM OF ACTI$8,556
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I, OPEN LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNE F$6,061
M01 · FY2008 · RR · contact PI
In Vivo Imaging of Antigen-Specific T Cells in Mice and Humans$258,097
P50 · FY2007 · CA · contact PI
A PHASE I, OPEN LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNE FUNCTION EFFEC$4,809
M01 · FY2007 · RR · contact PI
REDOSING WITH CP-675,206 IN SUBJECTS WITH CLINICAL BENEFIT ENROLLED IN A PHAS$1,030
M01 · FY2007 · RR · contact PI
In Vivo Imaging of Antigen-Specific T Cells in Mice/Huma$162,491
P50 · FY2006 · CA · contact PI
AFP-Based Immunotherapy for Hepatocellular Carcinoma$126,880
K23 · FY2006 · CA · contact PI
A PHASE I, OPEN LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNE FUNCTION EFFEC$13,613
M01 · FY2006 · RR · contact PI
REDOSING WITH CP-675,206 IN SUBJECTS WITH CLINICAL BENEFIT ENROLLED IN A PHAS$4,003
M01 · FY2006 · RR · contact PI
In Vivo Imaging of Antigen-Specific T Cells in Mice/Huma$162,491
P50 · FY2005 · CA
AFP-Based Immunotherapy for Hepatocellular Carcinoma$126,880
K23 · FY2005 · CA
A PHASE I, OPEN LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNE FUNCTION EFFEC$4,620
M01 · FY2005 · RR
REDOSING WITH CP-675,206 IN SUBJECTS WITH CLINICAL BENEFIT ENROLLED IN A PHAS$2,310
M01 · FY2005 · RR
AFP-Based Immunotherapy for Hepatocellular Carcinoma$126,880
K23 · FY2004 · CA
Redosing with CP-675,206 In Subjects With Clinical Benefit Enrolled In A Phas...$819
M01 · FY2004 · RR
AFP-Based Immunotherapy for Hepatocellular Carcinoma$126,880
K23 · FY2003 · CA
AFP-Based Immunotherapy for Hepatocellular Carcinoma$126,680
K23 · FY2002 · CA